Loading
InSphero
InSphero, a Swiss spin-off of ETH Zürich, makes tiny three-dimensional balls of human cells that behave more like real tissue than cells grown flat in a dish. Drug developers use its tumour spheroids, made from patients' tumours, to test cancer and immune drugs before trials in people.
Overview
InSphero was founded in 2009 as a spin-off from ETH Zürich and has offices in Schlieren, Switzerland, and Brunswick, Maine. It provides 3D in vitro models, microplates (Akura and Gri3D) and organ-on-chip platforms for drug discovery. For oncology and immunology it offers patient-derived primary tumour spheroids, which it says keep the epithelial, immune and stromal components of the original tumour, and models built from genomically characterised patient-derived xenografts, run in Akura 96- and 384-well plates for drug screening and for measuring tumour-immune interactions. In 2025 it signed a definitive agreement to acquire DOPPL SA, and in 2026 it acquired PhenoVista Biosciences of California.
Notes
- No cancer types are named on its oncology page, so no cancer is linked. Ownership and financing are not stated on the pages read. Headquarters is taken as the Schlieren office, which the company lists for Europe and the rest of the world; it does not name a headquarters. companyType cro-services is the corpus's nearest category for a model and screening-service provider.
Connected
2Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
insphero.com · 3
A source that has moved or gone is reported by the weekly link check. /audit/